/
QNCX
$34.22+$1.81 (+5.58%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$31.8M
1M shares
52-week range
$15.10 – $909.98
2% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Change$-367.78
Quince Therapeutics, Inc. Common Stock
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.
www.quincetx.com- Employees
- 38
- IPO / List date
- May 9, 2019
- HQ
- SOUTH SAN FRANCISCO, CA
Held by traders on TradeandTell
No one on the platform currently holds QNCX.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in QNCX as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-06-30 | 1-for-20reverse |
| 2026-04-13 | 1-for-10reverse |
Recent trades on TradeandTell
No one on the platform has traded QNCX yet.
